Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has U.S. offices in Palo Alto, CA and Philadelphia, PA, and has offices in various other locations in Europe. The company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. We plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our unique commercial expertise. As we evaluate additional acquisition and in-licensing opportunities, we work closely with healthcare professionals and patient advocates to identify significant treatment gaps where Jazz Pharmaceuticals’ unique approach to patient care and patient-focused products may be able to bring a new therapeutic option to the market where none existed previously.
Type
Public
Founded
2003
Employees
857 (est)+23%
Jazz Pharmaceuticals was founded in 2003

Key People at Jazz Pharmaceuticals

Heather McGaughey

Heather McGaughey

Senior Vice President, Human Resources
Fintan Keegan

Fintan Keegan

Executive Vice President, Technical Operations
Kathryn E. Falberg

Kathryn E. Falberg

Executive Vice President and Chief Financial Officer
Russell J. Cox

Russell J. Cox

Executive Vice President and Chief Commercial Officer
Bruce C. Cozadd

Bruce C. Cozadd

Chairman and Chief Executive Officer
Iain McGill

Iain McGill

Head of EUSA International and SVP, Jazz Pharmaceuticals

Jazz Pharmaceuticals Locations

Palo Alto, US
Ballsbridge, IE
Philadelphia, US
Oxford, GB

Jazz Pharmaceuticals Metrics

Jazz Pharmaceuticals Summary

Market capitalization

$6.1 B

Closing share price

$101
Jazz Pharmaceuticals's latest market capitalization is $6.1 B.

Jazz Pharmaceuticals Market Value History

Jazz Pharmaceuticals News

Jazz Pharmaceuticals Company Life

You may also be interested in